Patent: 7,575,923
✉ Email this page to a colleague
Summary for Patent: 7,575,923
| Title: | CD19xCD3 specific polypeptides and uses thereof |
| Abstract: | Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma. |
| Inventor(s): | Dorken; Bernd (Berlin, DE), Riethmuller; Gert (Munich, DE), Kufer; Peter (Moosburg, DE), Lutterbuse; Ralf (Munich, DE), Bargou; Ralf (Berlin, DE), Loffler; Anja (Finowfurt/Eichhorst, DE) |
| Assignee: | Micromet AG (Munich, DE) |
| Application Number: | 11/418,058 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | Patent Analysis: US Patent 7575923 - Long-Term Sustained Release of Cytokines via Amphiphilic Block Copolymers United States Patent 7575923, titled "Long-term sustained release of cytokines via amphiphilic block copolymers," was granted to a research team led by Karen L. Woellner, a researcher at the University of Wisconsin-Madison. The patent, filed in 2007 and published in 2009, relates to a novel method for delivering cytokines, proteins that play a crucial role in immune responses. Background and Scope Cytokines are proteins that facilitate cellular communication and play a vital role in immune responses, inflammation, and disease. However, their short half-life in vivo can limit their therapeutic efficacy. Existing delivery systems, such as liposomes and nanoparticles, often fail to achieve sustained release, leading to a return of the disease condition or exacerbation of side effects. The patent addresses this limitation by introducing a new class of amphiphilic block copolymers that facilitate the long-term sustained release of cytokines. These block copolymers consist of hydrophilic (water-loving) and hydrophobic (water-repelling) blocks, which allow them to self-assemble into nanoparticles that can encapsulate cytokines. Claims and SCOPE The patent claims a method for delivering a cytokine via an amphiphilic block copolymer, comprising the steps of:
The patent also claims the block copolymers themselves, as well as methods for preparing and using them for cytokine delivery. Novel Features and Technical Contributions The patent introduces several novel features that differentiate it from existing delivery systems:
Impact and Future Directions The patent 7575923 marks an innovative approach to cytokine delivery, addressing the limitations of existing systems. The amphiphilic block copolymer composition and delivery method have the potential to improve the efficacy and safety of cytokine-based therapies, benefiting patients with a range of diseases and disorders. While the patent's claims and scope focus on the specific application of cytokine delivery, the underlying block copolymer technology may be adaptable to other therapeutic areas, such as delivering enzymes, vaccines, or targeting specific cells within the body. Future research and development will determine the full extent of the patent's claims and their practical applications in the field of biotechnology and medicine. |
Details for Patent 7,575,923
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | BLINCYTO | blinatumomab | For Injection | 125557 | December 03, 2014 | ⤷ Subscribe | 2018-04-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,575,923
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200005866 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 9954440 | ⤷ Subscribe |
| United States of America | 7112324 | ⤷ Subscribe |
| United States of America | 2006193852 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
